Publications by authors named "Soudabeh Rad Pour"
Background: While programmed cell death receptor 1 (PD-1) blockade treatment has revolutionized treatment of patients with melanoma, clinical outcomes are highly variable, and only a fraction of patients show durable responses. Therefore, there is a clear need for predictive biomarkers to select patients who will benefit from the treatment.
Method: To identify potential predictive markers for response to PD-1 checkpoint blockade immunotherapy, we conducted single-cell RNA sequencing analyses of peripheral blood mononuclear cells (PBMC) (n=8), as well as an in-depth immune monitoring study (n=20) by flow cytometry in patients with advanced melanoma undergoing treatment with nivolumab at Karolinska University Hospital.
Dysregulation of the kynurenine pathway has been regarded as a mechanism of tumor immune escape by the enzymatic activity of indoleamine 2, 3 dioxygenase and kynurenine production. However, the immune-modulatory properties of other kynurenine metabolites such as kynurenic acid, 3-hydroxykynurenine, and anthranilic acid are poorly understood. In this study, plasma from patients diagnosed with metastatic cutaneous malignant melanoma (CMM) was obtained before (PRE) and during treatment (TRM) with inhibitors of mitogen-activated protein kinase pathway (MAPKIs).
View Article and Find Full Text PDFArticle Synopsis
- The kynurenine pathway (KP), activated by indoleamine 2,3-dioxygenase1 (IDO1), is a promising area of study for combating tumor growth and enhancing immune responses in various cancers, though the role of its other metabolites like 3-hydroxy kynurenine (3-HK) and kynurenic acid (KYNA) is less understood.
- A study involving 368 melanoma patients linked the kynurenine pathway to T-cell activity in the tumor environment, revealing that activated CD4+ T-cells produced increased amounts of KYN and KYNA while showing signs of immune exhaustion.
- Analysis indicated differences in KMO and KYNU expressions between wild-type and mutated